Mithra Pharmaceuticals: INFORMATION ON THE TOTAL NUMBER OF VOTING RIGHTS (DENOMINATOR)
27 juin 2017 11h46 HE
|
Mithra Pharmaceuticals
Information on the total number of voting rights (denominator) Liège, Belgium, 27 June 2017 [5:45 pm CET] - Regulated information - In accordance with article 15 of the Act of 2 May 2007 on the...
Mithra Pharmaceuticals: ESTELLE® PHASE IIB RESULTS ON WELL-BEING AND BODY WEIGHT PUBLISHED IN LEADING PEER-REVIEWED JOURNAL
26 juin 2017 01h31 HE
|
Mithra Pharmaceuticals
PRESS RELEASE Estelle® Phase IIb results on well-being and BODY weight published in LEADING peer-reviewed journal European Journal Of Contraception and Reproductive Health Care publishes article...
Mithra Pharmaceuticals: MITHRA SUCCESSFULLY RAISES €26.1 MILLION
21 juin 2017 09h01 HE
|
Mithra Pharmaceuticals
NOT FOR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE UNLAWFUL PRESS...
Mithra Pharmaceuticals: MITHRA LAUNCHES A CAPITAL INCREASE BY MEANS OF A PRIVATE PLACEMENT VIA AN ACCELERATED BOOKBUILD OFFERING
21 juin 2017 02h10 HE
|
Mithra Pharmaceuticals
NOT FOR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE UNLAWFUL PRESS...
MITHRA COMPLETES RECRUITMENT FOR ADDITIONAL ESTELLE® SAFETY STUDY
21 juin 2017 01h16 HE
|
Mithra Pharmaceuticals
PRESS RELEASE MITHRA COMPLETES RECRUITMENT FOR ADDITIONAL estelle® SAFETY studY Safety study is part of the development of Estelle®, Mithra's combined oral contraceptive candidate Aim of the...
Mithra Pharmaceuticals: MITHRA RECEIVES ORPHAN DRUG DESIGNATION FROM EMA FOR E4 IN NEONATAL ENCEPHALOPATHY
09 juin 2017 01h30 HE
|
Mithra Pharmaceuticals
PRESS RELEASE Mithra RECEIVES ORPHAN DRUG DESIGNATION FROM EMA FOR E4 IN NEONATAL ENCEPHALOPATHY Orphan Drug Designation received from European Medicines Agency for Estetrol...
MITHRA SIGNS EXCLUSIVE AGREEMENT FOR TIBELIA® IN CANADA
06 juin 2017 11h45 HE
|
Mithra Pharmaceuticals
PRESS RELEASE Mithra signs Exclusive agreement for Tibelia® in Canada Tibelia® would be the first tibolone-based Hormone Therapy product available in Canada Marketing...
Mithra Obtains Marketing Authorization for Tibelia in France
29 mai 2017 11h45 HE
|
Mithra Pharmaceuticals
PRESS RELEASE Mithra obtains marketing authoriZation for Tibelia® in France French MA completes decentralized procedure with MAs granted in 15 European countries Tibelia® is currently...
MITHRA RECEIVES GMP APPROVAL FOR MYRING(TM) PRODUCTION
23 mai 2017 01h30 HE
|
Mithra Pharmaceuticals
mithra receives gmp approval for myring(TM) production On track to file for marketing approval of hormonal contraceptive MyringTM in EU and US in Q2 2017 Approval ensures Mithra fully...
MITHRA AND GYNIAL SIGN COMMERCIALIZATION AGREEMENT FOR MYRINGTM IN AUSTRIA
19 mai 2017 01h30 HE
|
Mithra Pharmaceuticals
PRESS RELEASE Mithra AND Gynial SIGN COMMERCIALIZATION AGREEMENT FOR MyringTM in Austria Mithra grants non-exclusive 10-year license for vaginal contraception ring MyringTM to...